๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling
NCT06813274Diabetes Mellitus, Diabetic Retinopathy, Cognitive Impairment, Neurovascular Coupling
Hejiang Ye
Phase 2
160
Chengdu, Deyang, Guangyuan
2026-01-01
Not yet open
UDCA to Prevent Post-TIPS Hepatic Encephalopathy
NCT07273734Hepatic Encephalopathy (HE), TIPS
West China Hospital
Not applicable
270
Chengdu
2026-01-01
Active, closed
Gamified Neurology Grand Rounds
NCT07419984Education, Medical, Grand Rounds
West China Hospital
Not applicable
240
Chengdu
2026-01-01
Not yet open
Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer
NCT07299318Papillary Thyroid Carcinoma
West China Hospital
Observational
3,200
Chengdu
2026-01-01
Recruiting
The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms
NCT07310056Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Perioperative Management
West China Hospital
Not applicable
126
Chengdu
2026-01-01
Recruiting
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
NCT07295262Liver Cancer, Adult
West China Hospital
Phase EARLY_PHASE1
30
Chengdu
2026-01-01
Not yet open
IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial
NCT07336927Acute Ischemic Stroke Due to Medium-vessel-occlusion
Bo Wu
Not applicable
614
Chengdu
2026-01-01
Recruiting
Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
NCT07295340Liver Cancer
West China Hospital
Observational
20
Chengdu
2026-01-01
Not yet open
Cellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer
NCT07311317Breast Cancer Early Stage Breast Cancer (Stage 1-3)
West China Hospital
Observational
165
Chengdu
2026-01
Not yet open
A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
NCT07338396Non Small Cell Lung Cancer NSCLC
Guangzhou University of Traditional Chinese Medicine
Observational
3,000
Beijing, Guangzhou, Weihui, Shanghai, Chengdu
2026-01
Recruiting
The Association Between Primary Aldosteronism and Cognitive Dysfunction
NCT07304674Primary Aldosteronism, Cognitive Dysfunction, Mild Cognitive Impairment (MCI), Dementia
Xinjiang Medical University
Observational
1,000
Chengdu, รœrรผmqi
2025-12-31
Recruiting
Web-based Platform for Nutrition Management in Patients With Cancer
NCT07307404Nutrition
Xingchen Peng
Not applicable
84
Chengdu
2025-12-30
Recruiting
Early Warning and Stratified Diagnosis of Postoperative Respiratory Failure Based on Ventilator Waveform Image Features
NCT07799636Postoperative Respiratory Failure
West China Hospital
Observational
250
Chengdu
2025-12-29
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou
2025-12-22
Recruiting
Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)
NCT07313618Oculocutaneous Albinism (OCA)
West China Hospital
Phase EARLY_PHASE1
18
Chengdu
2025-12-22
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT07252739Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
140
Nanjing, Nanchang, Shanghai, Chengdu
2025-12-19
Recruiting
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
NCT07035249DCSZ11, Solid Tumors, HNSCC
West China Hospital
Phase 1/2
9
Chengdu
2025-12-16
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Not yet open
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Not yet open
CAR-T for Claudin18.2 Positive Solid Tumors
NCT07266311Claudin18.2 Positive Advanced Solid Tumors
Chengdu Ucello Biotechnology Co., Ltd.
Phase EARLY_PHASE1
18
Chengdu
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Not yet open
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
NCT07297875Achondroplasia
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Not yet open
CD19/BCMA CAR-T for SLE
NCT07266337SLE - Systemic Lupus Erythematosus
Chengdu Ucello Biotechnology Co., Ltd.
Phase EARLY_PHASE1
24
Chengdu
2025-12-10
Recruiting
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07274852Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-12-10
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07232524Head and Neck Squamous Cell Carcinoma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
16
Chengdu
2025-12-10
Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
NCT07269210Severe Hypertriglyceridemia
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Active, closed
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776Thyroid Eye Disease (TED)
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
NCT07255404Pancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 3
500
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Not yet open
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
NCT07277504B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command
Phase EARLY_PHASE1
50
Chengdu
2025-12-01
Active, closed
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
NCT07257497Solid Tumor Cancer
West China Hospital
Phase 1
20
Chengdu
2025-12-01
Recruiting
The Power of Belief: Expectation-driven and Placebo Modulation of Empathic Pain
NCT07367672Healthy Participants
University of Electronic Science and Technology of China
Not applicable
120
Chengdu
2025-12-01
Not yet open
A Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple Mastectomy
NCT07257003Breast Cancer
Du Zhenggui
Not applicable
150
Chengdu
2025-12-01
Not yet open
Allogeneic UCB-derived CAR-T for B-ALL
NCT07256353B-Cell Acute Lymphoblastic Leukemia, Adult
The General Hospital of Western Theater Command
Phase EARLY_PHASE1
50
Chengdu
2025-12-01
Not yet open
Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery
NCT07274696Patients Undergoing Open Thyroid Surgery
West China Hospital
Phase 3
528
Chengdu
2025-12-01
Not yet open
Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR
NCT07237828Breast Cancer
Du Zhenggui
Not applicable
379
Chengdu
2025-12-01
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682Non-Small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
NCT06909773Cardiovascular Diseases
AstraZeneca
Not applicable
3,000
Anqing, Beijing, Changsha, Chaohu, Chengdu, Chifeng, Chongqing, Dalian
2025-11-28
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOYยฎ (US-Sourced YERVOYยฎ) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
NCT07650084Refractory Chronic Cough
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Active, closed
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
NCT07216976Parkinson's Disease
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Recruiting
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
West China Hospital
Phase 1/2
84
Xiamen, Chengdu
2025-11-18
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xiโ€™an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT07232407Gastrointestinal Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-11-14
Recruiting
Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study
NCT07601711Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection, Pneumonia, Sepsis
Sichuan Provincial People's Hospital
Observational
200
Chengdu
2025-11-11
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
NCT07215585Large B-cell Lymphoma
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hefei
2025-11-11
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, รœrรผmqi
2025-11-06
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
PULSAR Combined With Immunotherapy and Chemotherapy
NCT07291947Cholangiocarcinoma
Wang Xin
Phase 1/2
60
Chengdu
2025-11-04
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
NCT06144671Advanced Solid Tumors
Grit Biotechnology
Phase 1/2
78
Shanghai, Chengdu
2025-11-01
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
NCT07327840Lipoprotein Disorder
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changchun, Changde, Changsha, Chengdu, Chongqing, Dali
2025-10-29
Active, closed
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT07220109Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Nanchang, Beijing, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nantong
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
NCT07053072Liver Cancer
West China Hospital
Phase 1
9
Chengdu
2025-10-23
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
NCT07272434Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
NCT07229950Adult Patients With Moderately to Severely Active Ulcerative Colitis
Shandong Suncadia Medicine Co., Ltd.
Phase 2
48
Chengdu
2025-10-17
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Recruiting
Non-pharmacological Auditory and Somatosensory Stimulation in Anesthetic Emergence
NCT07339618General Anesthetic, Electroencephalographic
West China Hospital
Not applicable
205
Chengdu
2025-10-11
Recruiting
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
NCT07308548NAFLD (Non-alcoholic Fatty Liver Disease)
Hinova Pharmaceuticals Inc.
Phase 2
80
Beijing, Chengdu
2025-10-11
Not yet open
Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy
NCT07201259Malignant Tumors
West China Second University Hospital
Observational
40
Chengdu
2025-10-10
Recruiting
The Effects of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Anxiety Responses and Emotional Regulation
NCT07369908Healthy Male and Female Volunteers
University of Electronic Science and Technology of China
Not applicable
140
Chengdu
2025-10-09
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
Sanofi
Phase 3
980
Chengdu
2025-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Not yet open
Organ Dysfunction Changes in Acute Necrotizing Pancreatitis Patients With Sepsis Following Open Necrosectomy
NCT07201246Necrotizing Pancreatitis
West China Hospital
Observational
700
Chengdu
2025-10-05
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Not yet open
Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus
NCT06663553Enlarged Uterus, Adenomyosis, Uterine Fibroids (UF)
West China Second University Hospital
Not applicable
210
Chengdu
2025-10-01
Recruiting
Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy
NCT07260526Rectal Cancer
West China Hospital
Observational
60
Chengdu
2025-10-01
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
Recruiting
Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over
NCT07233616Chronic Venous Insufficiency, CVI, Radiofrequency Ablation, Octogenarians(Aged 80 and Over), Cohort Study
Chengdu University of Traditional Chinese Medicine
Observational
50
Chengdu
2025-10-01
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
283
Changsha, Chengdu, Wuhan
2025-10-01
Rows per page Showing 301–400 of 1291
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.